Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Q3 2026 › vs Q3 2025
Kiniksa Pharmaceuticals International (KNSA) Q3 2026 vs Q3 2025 (year over year)
Kiniksa Pharmaceuticals International's revenue rose $105M (+58%) from $181M in Q3 2025 to $286M in Q3 2026. Operating margin 19.0% against 13.3% (+5.7 pts).
Kiniksa Pharmaceuticals International, Q3 2026: revenue $286M (+58% year over year), operating margin 19.0%, net earnings $47.3M, operating cash flow $47.5M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 19.0% | 13.3% | +5.7 pts |
| Net margin | 16.6% | 10.2% | +6.4 pts |
| Free cash flow margin | 16.6% | 18.2% | -1.7 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $286M | $181M | $105M | +58% |
| Other income, net | $4.8M | $3.1M | $1.7M | +54% |
| Operating profit | $54.2M | $24.0M | $30.2M | +126% |
| Costs & expenses | $232M | $157M | $74.9M | +48% |
| Pre-tax earnings | $59.1M | $27.2M | $31.9M | +117% |
| Cost of revenue | $27.8M | $20.3M | $7.5M | +37% |
| Research & development | $32.8M | $24.2M | $8.6M | +36% |
| SG&A | $65.4M | $49.1M | $16.3M | +33% |
| Other operating costs | $106M | $63.3M | $42.5M | +67% |
| Net earnings | $47.3M | $18.4M | $28.9M | +157% |
| Income tax | $11.7M | $8.7M | $3.0M | +34% |
| Depreciation & amortization | $490K | $384K | $106K | +28% |
| Share-based compensation | $13.1M | $10.1M | $2.9M | +29% |
| Working capital & other | $13.4M | −$4.7M | $18.1M | — |
| Operating cash flow | $47.5M | $33.7M | $13.9M | +41% |
| Free cash flow (OCF − capex) | $47.4M | $33.0M | $14.4M | +44% |
| Capital expenditures | $180K | $671K | −$491K | -73% |
Questions
How much did Kiniksa Pharmaceuticals International's revenue grow year over year in Q3 2026?
Kiniksa Pharmaceuticals International's revenue rose $105M (+58%) from $181M in Q3 2025 to $286M in Q3 2026. Operating margin 19.0% against 13.3% (+5.7 pts).